Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of IKT-001PRO for Cancers

Trial Profile

A clinical trial of IKT-001PRO for Cancers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IKT 001PRO (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Inhibikase Therapeutics
  • Most Recent Events

    • 08 Apr 2021 New trial record
    • 01 Apr 2021 According to Inhibikase Therapeutics, the company plans to file an Investigational New Drug application (of IkT-001Pro as a film-coated tablet) in the second quarter of 2021. This regulatory filing is anticipated to be completed near the end of the second quarter of 2021, with initiation of clinical development in 30 days after the filing. company expect to initiate clinical development early in the third quarter.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top